List of Excipients in Branded Drug DATSCAN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medi-Physics Inc dba GE Healthcare	DATSCAN	ioflupane i-123	17156-210	ACETIC ACID
Medi-Physics Inc dba GE Healthcare	DATSCAN	ioflupane i-123	17156-210	ALCOHOL
Medi-Physics Inc dba GE Healthcare	DATSCAN	ioflupane i-123	17156-210	SODIUM ACETATE

DATSCAN Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

DaTscan is a sterile, injectable radiopharmaceutical containing ioflupane I-123 for brain SPECT imaging of the dopamine transporter. Its commercial formulation is deliberately simple: ethanol for solubilization, an acetate/acetic acid buffer system for pH control, and water for injection. The main commercial opportunities are in sterile radiopharmaceutical manufacturing, excipient supply, container-closure systems, dose standardization, and reformulation for radiopharmacy workflow efficiency. The largest technical barriers are short radionuclide half-life, radiolysis, sterile production, and the need to preserve radiochemical purity and biodistribution.

What is DaTscan and how is it regulated?

DaTscan contains ioflupane I-123, a cocaine analog that binds to presynaptic dopamine transporters in the striatum. The product is used with SPECT imaging in adults with suspected Parkinsonian syndromes. It assists in differentiating essential tremor from tremor associated with Parkinsonian syndromes, but it does not distinguish Parkinson disease from multiple system atrophy or progressive supranuclear palsy [1].

Attribute	DaTscan profile
Active ingredient	Ioflupane I-123
Therapeutic category	Diagnostic radiopharmaceutical
Imaging modality	Brain SPECT
Radionuclide	Iodine-123
Physical half-life	Approximately 13.2 hours
Route	Intravenous injection
U.S. approval	FDA-approved under NDA 022454
Commercial sponsor	GE HealthCare
Dosage form	Sterile solution for injection
Primary use	Dopamine transporter imaging

The short half-life makes DaTscan a time-sensitive product. Manufacturing, release testing, shipment, administration, and imaging must be coordinated within a narrow operating window. That constraint materially changes the excipient strategy compared with conventional small-molecule injections.

What excipients are used in DaTscan?

The DaTscan formulation uses a low-complexity excipient system:

Excipient	Primary formulation function	Commercial relevance
Ethanol	Solubilization and vehicle support	Requires control of concentration, extractables, flammability, and container compatibility
Acetic acid	Acid component of buffer system	Controls pH and supports formulation stability
Sodium acetate	Buffer component	Controls pH during storage and administration
Water for injection	Sterile aqueous vehicle	Requires parenteral-grade supply and validated sterile handling

The U.S. prescribing information identifies acetic acid, sodium acetate, ethanol, and water for injection as inactive ingredients [1]. European product information similarly identifies the acetate buffer system, ethanol, and water for injections [2].

The formulation is not designed to maximize excipient differentiation. It is designed to provide adequate solubility and stability while minimizing components that could interfere with radiochemical quality, SPECT interpretation, intravenous administration, or regulatory comparability.

Why does ethanol matter in the DaTscan formulation?

Ethanol is likely the most commercially significant excipient in the product because it supports solubilization of the lipophilic ioflupane molecule. It also affects manufacturing, packaging, transport, and administration.

Key development considerations include:

1. Ethanol concentration must remain within a validated range.
2. The formulation must maintain radiochemical purity through the labeled shelf life.
3. Vial, stopper, and syringe materials must be compatible with ethanol.
4. Extractables and leachables must be assessed under the actual formulation conditions.
5. The administered ethanol exposure must remain clinically acceptable at the labeled dose.
6. Sterile manufacturing controls must account for ethanol handling and flammability.

A lower-ethanol formulation could have commercial value if it improves tolerability, container compatibility, or radiopharmacy handling. The opportunity is technically difficult because reducing ethanol could lower ioflupane solubility or change adsorption to vial and syringe surfaces.

A replacement solvent or cosolvent would require comparative testing of:

• Appearance and particulate matter
• Radiochemical purity
• Chemical purity
• Free iodide formation
• Ioflupane adsorption
• Biodistribution
• Striatal-to-background imaging ratios
• Sterility and endotoxin limits
• Container-closure integrity
• Stability under radioactive decay conditions

What role does the acetate buffer system play?

Acetic acid and sodium acetate create an acetate buffer that controls formulation pH. pH is important because it can affect:

• Ioflupane chemical stability
• Iodine-123 labeling stability
• Radiolytic degradation
• Vial and stopper compatibility
• Injection tolerability
• Formation of degradation products

A buffer change is unlikely to be commercially meaningful unless it solves a defined manufacturing or distribution problem. Potential objectives include longer usable dating, improved radiochemical stability, lower extractables, or better compatibility with automated dispensing systems.

The principal opportunity is not a new buffer for its own sake. It is a validated formulation package that reduces dose loss, limits radiolysis, and improves operational reliability at radiopharmacies.

How does radioactivity change excipient selection?

Iodine-123 has a half-life of approximately 13.2 hours. The formulation therefore experiences a changing radiation environment between production and administration. Radiolysis can generate reactive species that alter the active ingredient or excipients.

Excipient screening should assess:

• Peroxide and aldehyde impurities in ethanol
• Dissolved oxygen
• Trace metals
• Buffer concentration
• Light exposure
• Headspace composition
• Vial surface adsorption
• Radiation-induced pH drift
• Formation of radiolabeled or nonradioactive degradants

Conventional antioxidant strategies require caution. Antioxidants can interfere with labeling chemistry, alter biodistribution, introduce new impurities, or create additional regulatory complexity. A lower-risk approach is often control of raw-material quality, oxygen exposure, light, container materials, and process timing.

For radiopharmaceutical developers, the highest-value excipient innovation may therefore involve a complete stability-control system rather than a novel chemical additive.

What formulation patents protect DaTscan?

DaTscan’s commercial value is tied to ioflupane I-123 production, radiolabeling, formulation, sterile manufacture, and clinical imaging use. Public regulatory materials identify the product and its formulation but do not establish a broad, standalone patent estate around the marketed excipients [1,2].

The practical IP position should be divided into four categories:

IP category	Relevance to DaTscan
Active ingredient and precursor chemistry	May protect ioflupane intermediates, stereochemistry, or synthesis
Radiolabeling process	May cover incorporation of I-123 and purification
Formulation	May cover solvent, buffer, concentration, pH, or stability parameters
Method of use	May cover dopamine transporter imaging or diagnostic applications

An excipient supplier is unlikely to obtain meaningful market exclusivity merely by supplying standard ethanol, sodium acetate, acetic acid, or water for injection. Commercial protection is more likely to arise from a proprietary low-ethanol formulation, a validated container-closure system, an automated dose-delivery process, or a manufacturing method that materially improves radiochemical yield or usable dating.

What is the Orange Book status of DaTscan?

DaTscan was approved in the United States under NDA 022454 [1]. The Orange Book is relevant to small-molecule drug patents and regulatory exclusivity, but the commercial significance of listed patents must be assessed against the product’s age, the scope of any listed claims, and the short-lived nature of the radionuclide.

The principal market-access questions are:

• Whether current patents are listed against NDA 022454
• Whether any listed claims cover the marketed formulation
• Whether claims cover ioflupane synthesis or radiolabeling
• Whether an abbreviated or 505(b)(2) applicant could rely on the reference product
• Whether a competing applicant would need to conduct bridging imaging or clinical studies

A current Orange Book review should be performed before relying on any patent expiration date or Paragraph IV strategy. The FDA label confirms the NDA and formulation but does not itself establish the complete current patent listing position [1].

When does DaTscan lose exclusivity?

DaTscan’s key regulatory exclusivity periods are historical rather than an immediate commercial barrier. The product received U.S. approval in 2011. Standard new chemical entity exclusivity, if applicable to the approved active ingredient, would have expired years ago. The current competitive protection is more likely to depend on manufacturing capability, radiopharmacy distribution, regulatory data requirements, and any surviving patent claims than on basic regulatory exclusivity.

Exclusivity or access factor	Commercial assessment
New chemical entity exclusivity	Historical; no longer the primary barrier
Orphan exclusivity	Not the principal known commercial protection
Pediatric exclusivity	No central commercial role identified
Formulation patents	Must be verified through current patent and Orange Book review
Method-of-use patents	May affect specific diagnostic claims
Manufacturing know-how	Potentially important, especially for radiolabeling and purification
Distribution network	Material because I-123 decays rapidly
Clinical interpretation capability	Supports brand retention and customer relationships

Which companies could challenge DaTscan?

Potential competitors fall into different categories:

Generic or 505(b)(2) radiopharmaceutical manufacturers

A competing applicant could pursue a product based on the same active moiety and route of administration. The principal challenges would include:

• Demonstrating equivalent radiochemical and chemical quality
• Establishing comparable biodistribution
• Matching specific activity and dosing performance
• Validating a short shelf life
• Building regional distribution capacity
• Meeting radiopharmaceutical manufacturing and radiation-safety requirements

A 505(b)(2) pathway may be more practical than a conventional generic pathway if formulation, labeling, imaging performance, or clinical bridging requirements differ from the reference product.

Nuclear pharmacy manufacturers

Large nuclear pharmacy operators may have the infrastructure to produce or distribute competing products. Their advantage is proximity to hospitals and SPECT centers. Their risk is the need for validated production, reliable isotope supply, batch release, and predictable patient scheduling.

Radiopharmaceutical specialists

Specialty radiopharmaceutical companies may compete through alternative dopamine transporter imaging agents, improved kit formats, or regional supply models. A direct substitute would need to generate clinically interpretable images and obtain regulatory approval for a comparable diagnostic use.

What excipient-based commercial opportunities exist?

1. Low-ethanol or ethanol-free formulation

A reduced-ethanol formulation could improve handling and expand compatibility with automated dispensing equipment. Its value depends on maintaining solubility, radiochemical purity, and imaging performance.

2. Improved container-closure systems

A vial and stopper combination optimized for ethanol, radioactive decay, and low adsorption could reduce dose loss. Suppliers could differentiate through:

• Low-extractables elastomers
• Low-binding glass or polymer surfaces
• Improved closure integrity
• Radiation-compatible materials
• Validated syringe transfer systems

3. Ready-to-use unit-dose presentations

DaTscan is administered in a clinical workflow where time and dose accuracy matter. Unit-dose or premeasured presentations could reduce manipulation at nuclear pharmacies and imaging centers. The business case depends on maintaining accurate activity at administration despite radioactive decay.

4. Radiopharmacy workflow products

Commercial opportunities include:

• Automated dose dispensing
• Barcoded activity tracking
• Calibrated syringes
• Low-dead-volume transfer devices
• Shielded single-dose packaging
• Integrated quality-control kits

These products may produce more practical value than a new excipient because they address dose loss and operational complexity directly.

5. Regional sterile fill-finish

The short half-life supports geographically distributed manufacturing or finishing. A regional network could reduce transit time and improve the proportion of doses administered before decay. Opportunities exist for contract manufacturing organizations with:

• Radioisotope handling licenses
• Sterile fill-finish capacity
• Validated radiochemical testing
• Nuclear pharmacy distribution
• Hospital delivery networks

6. Alternative imaging agents

The strongest long-term competitive opportunity may be an alternative dopamine transporter radiopharmaceutical with improved availability, longer effective distribution range, or simpler manufacture. An excipient improvement alone is unlikely to displace DaTscan unless it produces a measurable advantage in image quality, supply reliability, or cost.

How strong is the DaTscan formulation patent estate?

The formulation estate appears more difficult to build around standard excipients than around process and manufacturing know-how. Ethanol, acetate, and water are established pharmaceutical materials. A patent covering their mere presence would face substantial novelty and obviousness challenges.

A stronger formulation patent would require a specific technical result, such as:

• A defined ethanol concentration range that improves stability
• A buffer ratio that reduces radiolysis
• A container system that reduces adsorption
• A composition that maintains radiochemical purity through a longer dating period
• A manufacturing sequence that improves yield
• A low-volume presentation that improves delivered activity

Claims should be supported by comparative data against the marketed formulation. Without measurable performance differences, excipient claims are likely to provide limited exclusionary value.

What litigation, settlements, and Paragraph IV risks affect DaTscan?

No major, widely reported Paragraph IV litigation or settlement involving the marketed DaTscan excipient system is established in the core FDA and European regulatory materials cited here [1,2]. The more credible competitive risk is a regulated alternative that avoids any surviving formulation or process claims and enters through a generic, 505(b)(2), or independent radiopharmaceutical pathway.

A challenger would likely focus on:

1. Non-infringement of formulation claims
2. Invalidity of narrow excipient ranges
3. Independent manufacture of ioflupane I-123
4. Alternative vial and syringe materials
5. Distinct labeling or imaging claims
6. Regional supply through licensed nuclear pharmacies

Settlement economics would depend less on conventional tablet-generic volume and more on site-specific radiopharmacy capacity, hospital contracts, isotope supply, and reimbursement.

What is the revenue exposure and competitive outlook?

GE HealthCare does not publicly disclose DaTscan revenue as a separate product line in the cited regulatory materials. Product-level revenue exposure therefore cannot be quantified from the FDA label or European product information.

The commercial profile has several characteristics:

• The market is diagnostic rather than therapeutic.
• Dose volume is constrained by clinical use and isotope decay.
• Revenue depends on imaging-center utilization and geographic availability.
• Supply interruptions can shift demand quickly to alternative diagnostic approaches.
• Formulation improvements have value when they reduce failed doses, late deliveries, or discarded activity.
• Competitive entry is operationally more difficult than entry for a conventional nonradioactive injectable.

Key Takeaways

• DaTscan uses a simple excipient system based on ethanol, acetic acid, sodium acetate, and water for injection.
• Ethanol is the main formulation variable because it supports solubilization but creates compatibility and handling requirements.
• Acetate buffering controls pH and contributes to chemical and radiochemical stability.
• The most valuable formulation opportunity is a validated stability and delivery package, not an isolated new excipient.
• Low-ethanol formulations, low-adsorption containers, unit-dose presentations, and automated dispensing systems have commercial potential.
• Radioisotope half-life makes regional manufacturing, dose logistics, and radiopharmacy workflow central competitive factors.
• DaTscan’s historical regulatory exclusivity is no longer the main barrier to competition.
• Current patent and Orange Book records should be reviewed before relying on any specific expiration date or Paragraph IV theory.
• No product-level DaTscan revenue figure is established in the cited public regulatory sources.
• A successful competitor would need to solve manufacturing, distribution, regulatory, and imaging-validation issues together.

FAQs

Can ethanol be removed from DaTscan without changing the product?

Possibly, but removal could reduce ioflupane solubility, increase adsorption, and alter radiochemical stability. An ethanol-free formulation would require comparative quality, stability, biodistribution, and imaging data.

Are the DaTscan excipients eligible for pharmaceutical-grade supply contracts?

Yes. Ethanol, sodium acetate, acetic acid, and water for injection can be supplied under pharmaceutical quality systems. Suppliers would need appropriate compendial compliance, impurity controls, documentation, and change-control support.

Could a competing company commercialize a DaTscan-like product with different excipients?

Potentially. A competing product could use a different solvent or buffer if it satisfies applicable regulatory requirements and demonstrates comparable safety, quality, radiochemical purity, biodistribution, and imaging performance.

Does DaTscan have biosimilar competition?

No. DaTscan is a radiolabeled small-molecule diagnostic product, not a biologic. Biosimilar legislation is therefore not the relevant competitive pathway.

What is the most defensible patent strategy for a DaTscan reformulation?

The strongest strategy would target a defined composition or container-process combination supported by measurable improvements in radiochemical stability, delivered dose, shelf life, adsorption, or radiopharmacy throughput.

References

1. U.S. Food and Drug Administration. (2024). DaTscan (ioflupane I 123 injection) prescribing information. FDA.

2. European Medicines Agency. (2024). DaTSCAN: Product information. EMA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. International Atomic Energy Agency. (2023). Radioisotopes and radiopharmaceuticals in nuclear medicine. IAEA.